- * -

NASER L. REZK, PHD

OFFICE: Taibah University, HOME: 2705 Becketts Ridge, Drive

Faculty of Applied Medical Sciences Hillsborough, NC 27278 Work Phone: 014-******* 919-***-**** (home US)

Cell phone: 966********* 919-***-**** (MJ)

Fax: 966***-******* acsdcv@r.postjobfree.com

acsdcv@r.postjobfree.com acsdcv@r.postjobfree.com

Citizenship: American citizen

MISSION STATEMENT

I do believe that our responsibility is to prepare individuals for lives of intellectual, professional, and civic integrity, in which diversity and service to others are valued and practiced. TAIBAH UNIVERSITY TEACHING STATEMENT

I respect student abilities and needs. With patience, humor, and tolerance for the occasional false start or stumble, I’m teaching students, that they are capable of maximizing learning of much more than they have had a chance to realize. My responsibilities include setting and modeling high standards that ask students to think, ask questions, and write notes to the best of their abilities. Then, help students to recognize what they’ve accomplished so they can internalize these standards for future practical work atmosphere.

Since grades at the end of each term, punctuate learning not with a full stop, but with a comma. I structure practical courses as well as theoretical themes that lead to a final assignment simultaneously releasing students from the course and giving them questions to pursue later. My teaching goal at Taibah University is to inspire student to initiate critical thinking. Critical thinking will assist them to create a problem solving capability with patience, joy, and high professional standard. I respect student needs by recognizing that they move with the motivation from one section to another which requires evaluation and a measure of courage.

The connectivity between theory and practice are missing in many colleges programs. I do believe that in order to produce that graduate who can join the job market with confidence especially in the field clinical laboratory sciences; we must prepare him for connecting the theory with jobs’ needs. As a professor who starts his career as medical technologist, I'm passing my practical experience to new generations. From

- 2 -

my training experience at UNC-CH, USA, I have learned that medical technologist with good attention to laboratory data has better success in their career. But those who are the focus only on the theoretical side do not produce high quality data which is tremendously important as an outcome of the clinical laboratory. Therefore, they suffer in their work place. Currently, I’m teaching my students the connection between good work practice and course/classroom knowledge. EDUCATION

2007 Doctor of Philosophy in Biochemistry (PhD thesis, Pharmacotherapy) Department of Biochemistry Chemistry

Tanta University Tanta, Egypt

Practical work course done at University of North Carolina Pharmacotherapy & Experimental Therapeutics, UNC, Chapel Hill, NC, USA

1994 Master of Science in Biochemistry

Department of Chemistry and Biochemistry

El-Menoufia University, El-Menoufia, Egypt

MS Thesis: “Determination of theophylline in different body fluids” Thesis including; developing methodologies for Therapeutic Drug monitoring (TDM) of theophylline and other ethylated xanthenes in human body fluids (Blood Plasma, Saliva, and Urine). 1983 BS of Science in Chemistry

College of Sciences

El-Menoufia University, El-Menoufia, Egypt

“All educational credentials have been evaluated through Evaluation of international educational credentials “American Association of Collegiate Registers and Admissions Officers (AACRAO) Washington DC, USA”

EXPERTISE

Over twenty-five years of academic research experience in; laboratory science, clinical pharmacology, pharmaceutical industry and medical technology fields, developing new technologies, validating research methodologies and strategically designed many successful research core laboratory

- 3 -

facilities. In addition to analytical/ bioanalytical research and projects development, I’ve developed and directed several business models such; core lab facility, independent clinical laboratory and bioequivalent/bioavailability center. I’ve developed research team for applications in clinical pharmacology, drug formulation, drug quality control, therapeutic drug monitoring and biomedical research with world class level of strong background, and research experience in AIDS treatment and HIV-prevention.

In addition:

1. Dr. Naser L. Rezk, PhD is the founder of the CPACL (AIDS) laboratory at The UNC, NC, USA. Dr. Rezk has planned and established Saudi National Research Lab and a BE/BA center at the Saudi National Guard in Riyadh, KSA

2. Teaching my grad/postgrad students the connection between good work practice and course/classroom knowledge

i) Design and operate research and services facilities/centers to update high technology ii) Increasing impact for international publications iii) Introduce scientific/technical solutions for clinical laboratories and by linking the academic institute with hospitals and industry

iv) Improve and grow teaching curriculums.

Design chromatography and mass spectrometry solutions suitable for industry and academia. Qualified speaker, facilitator of professional communication, and leader of fast growing organization. Strong interpersonal skills demonstrated with proven ability to collaborate effectively with individuals on all levels.

JOURNAL REVIEWER

1. Journal of Chromatography B. Biomedical sciences and applications (2003-Present). 2. Journal of Chromatography Symposium Volumes 2003. 3. Talanta, Fundamental theory and practice of analytical chemistry Journal (2003-Present). 4. JAOAC INTERNATIONAL (Journal of association of official chemists) Bioanalytical chemistry and Microbiological research. (2003-Present). 5. Journal of Pharmaceutical and Biomedical Analysis (2004-present) 6. Journal of Clinica Chemica Acata (2005-present) 7. Vaccine (2005-present)

8. Informa Health Care (2006-present)

9. Expert Opinion on Pharmacotherapy (2007-present)

- 4 -

10. Analytica Chimica Acta (2008-present)

11. Journal of Current Pharmaceutical Analysis (2008-present) 12. The Analyst RSC (2011)

13. Journal of Chromatography Science (2012)

14. Saudi Journal of Obesity SJO (2013)

JOURNAL EDITOR

o Journal of Analytical & Bioanalytical Techniques o Journal of Pharmaceutical and Bioanalytical Science (JPB Science) o Saudi Journal of Obesity

o World Journal of Clinical Pediatrics

HONORS AND AWARDS

o 2008: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2007: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2006: The State of North Carolina Governor Award of excellence for Innovation in Science.

-It is the highest honor that can be bestowed on a state level for service of the citizens of United State of America

o 2006: University of North Carolina at Chapel Hill (UNC-CH) Chancellor Award of excellence for Innovation in Science.

“Recognizing works and efforts in establishing the first Clinical Pharmacology& Analytical Chemistry Core’s “top ranking laboratory core facility among similar units" nationally and internationally in matter of quality, quantity and revenue” o 2006: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2005: Association of quality assessment in TDM and Clinical Toxicology Certificate (Gold Level)

o 2004: Association of quality assessment in TDM and Clinical Toxicology Certificate (Silver Level)

TRAINEESHIP

- 5 -

Dec 2010- Nov 2012 Badir Bio Technology Center, Riyadh, KSA Business planning, market evaluation and establishing biotechnology business project

Oct 1985 – Oct 1986 Medical Center

Medical technology training:

Hematology, Biochemistry (clinical biochemistry), Microbiology, Immunology and Serology

Jun 1996 – Jun 1997 Carolina Medical Center, Charlotte, NC, USA Medical technology training:

Clinical cytogenenetics

Dr. Frank Grass

July 1997 – May 1998 Plasmapheresis and Clinical Laboratory Technology Alpha therapeutic corporation

Charlotte, NC, USA

PROFESSIONAL WORK

Dec 2013 – Present Associate Professor, Taibah University Teaching Clinical Pharmacology, TDM, Clinical Toxicology, Forensic Science for clinical laboratories, Research methodologies & Planning to continue research in Pharmacology, Clinical Pharmacology, Experimental Therapeutics and Environmental Toxicology Jan 2013 – Present Research and Development Director (Remotely Advisor) Andor Labs Durham, NC,USA

Established strategic plan for the company expansion, adding more advanced technology and applications for better clinical laboratory services

Oct 2010 – Dec 2012 Associate Professor, King Saud bin Abdulaziz Medical Science University, Riyadh, KSA

Established strategic plan for Saudi National Research Laboratory at Saudi National Guard and Affiliated with King Saud bin Abdulaziz Health and Science University post-graduate program &Research Center (Laboratory Director)

- 6 -

King Abdullah International Medical Research Center, Riyadh, KSA, Building Bioequivalent (BA/BE) center, Riyadh, KSA Oct 2007 – Sep 2009 Assistant professor

Director of Clinical Pharmacology and Analytical Chemistry Core facility (CPAC)

The department of pharmacotherapy and experimental therapeutics, School of Pharmacy

University of North Carolina at Chapel Hill

Chapel Hill, NC

Jan 2000– Oct 2007 Research Associate (Lab Associate Director) UNC Center for Aids Research (CFAR) Clinical Pharmacology and Analytical Chemistry Core

University of North Carolina at Chapel Hill

Chapel Hill, NC

Dec 1996- Mar 2000 Research Scientist (USA Industry) Quality Control Chemist, Vintage Pharmaceuticals, Charlotte,NC

&Chemist, Department of Chemical Discovery, Rhone Poulenc/Avantis, RTP, NC & Formulation Chemist

Department of Drug Development and Formulation

Trimeris Inc., Durham, NC & Volunteer Scientist

Department of Clinical Genetics (Cytogenetics Laboratory) Canon Research Center, Carolina Medical Center, Charlotte, NC Jun 1986 – Dec 1995 Clinical Chemist (Research Assistant & MT) Health Center Laboratory, Al-Dewaneyah,Al-Qadesiyyah, Iraq

&Clinical Pharmacology Department, School of Medicine El-Menoufia University, El-Menoufia, Egypt

PROFESSIONAL AFFILIATIONS

Member and Fellow:

1. American Chemical Society (ACS) 1996-Present (member) 2. American Association for Clinical Chemistry (AACC) 2005-Prsent (member) 3. Advance for Medical Laboratory Professional 1996-Present (member) 4. American Association for the Advancement of Science 1996-Present

- 7 -

5. Toastmaster International 2001-2009 (president, leader, officer and organizer) 6. American Association of Colleges of Pharmacy (AACP) 2008-Present (member) 7. American society of clinical pathologists (ASCP) 2009-Presnt (invited member) RESEARCH AND DEVELOPMENT

Analytical clinical chemistry, pharmacology and TDM using Immunoassays, Spectrophotometery, Chromatography, Mass-spectrometry (HPLC, LC-MS, LC-MS/MS and GC/MS)

Clinical Pharmacology, Toxicology, and Therapeutic Drug Management of Antiretrovirous, Antipsychotic, and Opioids

Bioequivalent/Bioavailability laboratory and BE/BA studies CLINICAL LABORATORY CONSULTATION

-Clinical Laboratory Consultation Company (owner and CEO) http://rezklab.com/3.html

1. Clinical laboratory for doctors’ offices

2. Clinical chemistry for large medical centers

3. Clinical pharmacology and analytical chemistry laboratory core facilities 4. Bioequivelent/Bioavailability laboratories

5. Current activity building new department for drug potency and stability testing for compounding

6. Consultation services for building drug formulation laboratory Rezklab.com Services

1. Develop and/or provide guidance and scientific/technical support for developing new testing methodologies for laboratories to expand services including training lab staff on the new testing methods, follow up assuring the most accurate results obtained. 2. Managerial and financial services supporting working team to achieve the highest efficient laboratory operation.

3. Reviewing laboratory part of clinical studies to assure the plan is perfect in terms of getting cost efficient without sacrificing quality of the data. 4. Sharing research opinion and helping in getting good data published. 5. Building and reviewing budgets of laboratory projects including; governmental, academia, hospital, reference, and research laboratories.

- 8 -

6. Rezklab provides services to clinical and preclinical laboratories drug development and formulation. We are also able to support governmental and non-governmental agencies and laboratory manufacturers that are involved in the production of pharmaceutical products (drugs or medical devices) and financial institutions involved in financing and investing laboratory businesses.

7. Rezklab provides assistance in hiring laboratory staff specialized in all laboratory disciplines. 8. Pharmaceutical Companies Laboratory Consultation (USA Industry) GRANTS and CONTRACTS:

1. Rezk, NL, Principal investigator, Taibah University, Deanship grants 03, 2014 (97,000.00 SR) 2. Rezk, NL, Principal investigator, Taibah University, Call for application type of grants, grants 04, 2014 (74,000.00 SR)

3. Kashuba ADM and Rezk, NL, Principal Investigators, Shimadzu LC/MS Grant for Academic Institutions. 07/2005. $65,000.00

4. Rezk, NL. Principal investigador, Kashuba ADM. Co-Investigator. University of North Carolina Tibotec Therapeutic. Drunavir cervicovaginal secretion study, 03/2008. $140,361.00 5. Rezk, NL. Principal investigator, Kashuba ADM. Co-Principal investigator. University of North Carolina Conrad “Bioanalytical methods development and validation of UC-781 in rabbit, Human and Monkey” 07/2008. $456,572

6. Rezk, NL. Principal investigator, Kashuba ADM. Co-Principal investigator. University of North Carolina Conrad amendment on “Bioanalytical methods development and validation of UC-781 in rabbit, Human and Monkey” 02/2009 $68,486

7. Rezk, NL, Investigator. Antiretroviral Pharmacology in the Genital Tract. 4/03-2/08. K23 AI54980. $250,000,00

8. Rezk, NL, Core Associate Director. General Clinical Research Center. 01/06 – 06/08. M01- RR00046. $59,000.00

9. Rezk, NL, Co-Investigator. The Effect Of Tipranavir/Ritonavir On Steady-State Concentrations Of Omeprazole And Its Metabolites. Boehringer Ingelheim Pharmaceuticals, Inc. 12/2006 – 2/2007. $51,100.00

10. Rezk, NL Co- Investigator, Evaluating the Effects of Tipranavir (with Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity Using a Biomarker Cocktail in Healthy Human Volunteers. Boehringer Ingelheim Pharmaceuticals, Inc.

(Investigator-Initiated Research) 2/2006 – 2/2007. $1,668,280.00

- 9 -

11. Rezk, NL, Co-Principal Investigator, Shimadzu LC/MS Grant for Academic Institutions. 07/2005. $65,000.00

12. Rezk, NL, Co-Principal Investigator. Adult AIDS Clinical Trials Group. Clinical Pharmacology Support Laboratory. DAIDS (NIH). 1/2004-12/2005. $1,560,000.00 TEACHING & MENTORING& ACADEMIC APPOINTMENTS:

2004-2010 Assistant professor School of Pharmacy at The University of North Carolina at Chapel Hill, The Department of Pharmacotherapy & Experimental Therapeutics Teaching: Analytical Chemistry, Clinical/ Bioanalytical Chemistry, Instrumentation, Pharmacology & Biochemistry.

UNC Experimental Therapeutics Graduate Students

2001 – 2005 Mary Peace McRae, Pharm D, PhD Conferred May 2005 Understanding the Hepatotoxicity of Antiretroviral Drugs in the Treatment of HIV/AIDS

Using Bile acids profile as tool for Hepatotoxicity 2004 – 2006: Assistant Professor, Department of Pharmacology, Kansas City University of Medicine and Biosciences

2008 – 2009 Michael Cohen MD, PhD Conferred May 2007 2009: PhD student at DUKE University & UNC-School of Pharmacy and Duke pediatric residence program.

2008 – 2009 Latoya Griffin BS. PhD Conferred May 2006 2008– Present: PhD student at UNC-School of Pharmacy 2008 – 2009 Jasmine Talamah. Pharm D, PhD Conferred May 2008- UNC- School of pharmacy

UNC School of Pharmacy Research Fellows:

2003 – 2005 Rosa Yeh, Pharm.D, HIV Academic Research Fellow Hiba Tappouni, Pharm D, GlaxoSmithKline Research Fellow 2005 – 2007 Julie Dumond, Pharm D, HIV Pharmacology Research Fellow Manoli Vourvahis, Pharm D, GlaxoSmithKline Research Fellow

- 10 -

2008 – 2009 Amanda Johns Pharm D, HIV Pharmacology Research Fellow 2008 – 2009 Sunny Devi Paul MS, HIV Pharmacology Research Fellow 2008 – 2009 Kevin Brown Pharm D, Academic Research Fellow UNC School of Pharmacy Post-Doctoral Fellows:

2008 Li Hou, PhD National University of Singapore

UNC School of Pharmacy Full time Scientists (Hiring, training, supervising): 2004 – 2005 Shonda White, BS (Research Scientist)

2005 – 2009 Steve Jennings, BS (Research Specialist) 2006 – 2009 Nicole White, BS (Research Specialist) 2005 – 2007 Jun, Lee, BS (Research Scientist)

2006 – 2009 Tiffany Whiting, BS (Research Lab Technician) 2006 – 2007 Jisong Kim, BS (Research LabTechnician) 2007 – 2009 Ruili Wang, MD

2007 – 2009 Stephanie Malonie, MS

2008 – 2009 Sunny Qiao, MS

2009 – 2009 Wojciech L Krol, MS

International Visiting Scientists

05/2004 – 05/2005 Byung Hwa Jung, PhD,

Bioanalysis and Biotransformation Research Center

Korea Institute of Science and Technology

Seoul, South Korea

12/2005 – 12/2007 Sun Ok Choi, PhD

Senior Scientific Officer

Division of Biopharmaceutics

National Institute of Toxicological Research

Korea Food and Drug Administration

Seoul, South Korea.

International Visiting Scientist

2006 Prof. Mohamed F. Abdel-Megeed, PhD,

Department of Chemistry and Biochemistry

Faculty of Science, Tanta University, Tanat, Egypt.

- 11 -

International Visiting Scientist

2005 Anand Manoharan, PhD,

Microbiologist, Department of Medicine

Unit 1, Christian Medical College & Hospital

Vellore-632004, India

UNC School of Pharmacy Students:

2005 - 2006 Christina Sarrubbi, Pharm D. Candidate Comparison of 3 Hour Omeprazole and 5- hydroxyomeprazole Concentration Ratios to 24 Hour AUC Ratios as a Measure of Hepatic CYP2C19 Activity 2004 - 2005 Kevin Brown, Pharm D. Candidate

“A simple and sensitive bioanlytical assay for simultaneous quantitative determination of omeprazole and its three metabolites in human blood plasma” 2003 - 2004 Rustin Crutchley, Pharm D. Candidate

“Full validation of analytical method for the HIV protease Inhibitor atazanavir”

UNC Undergraduate Students:

2006 - 2007 Ji Song Kim (biochemistry major)

Saed Awdalla (chemistry major)

Oberlin University, OH, USA Undergraduate Students: 2007 Robert Hartley (Chemistry major)

Janice McMillan (Biology major)

2008 Samuel Alfiler (Chemistry major)

International Students

2003 Mwayi Kazembe, Malawi, Africa,

UNC Research Apprenticeship Program

2005 Susan Pendame, Malawi, Africa

UNC Research Apprenticeship Program

2006 Mahmoud Slamah, UNC Research Apprenticeship Program SELECTED PUPLICATIONS

- 12 -

1. Ghada Bin Saleha, Naser L. Rezk, Laila Laikad, Anna Alia, Ashraf El-Metwally, Pharmacist, the pharmaceutical industry and pharmacy education in Saudi Arabia: A questionnaire-based study, SJP, 23; 5 (2015) 573–580

2. Huda O. Salhiaa, Anna Alia, Naser L. Rezk, Ashraf El Metwallya, Perception and attitude of physicians toward local generic medicines in Saudi Arabia: A questionnaire-based study SJP, 23; 4

(2015) 397–404

3. Muzaffar Iqbal, Essam Ezzeldin, Khalid A. Al-Rashood, Yousif A. Asiri, Naser L. Rezk, Rapid determination of canagliflozin in rat plasma by UHPLC–MS/MS using negative ionization mode to avoid adduct-ions formation, Talanta 132 (2015) 29-36. 4. Naser NL, Husam Bagdadi, Saudi pharmaceutical market and pharmacy education 4th International Conference on Pharmaceutical Regulatory Affairs-2014. DOI: DOI: 10.4172/2167-7689.S1.014 5. Rezk NL, Qiao Z, Jeraisy M, Development and validation of an extraction method for the determination of UC781 in cervicovaginal fluid, AJAC, 4;12 (2013) 707-714. 6. Rezk NL, Analytical method for improving the use of UC-781 as a topical virginal microbisited, online, advanced in Engendering (2012).

7. Rezk NL, Wang R, Qiao Z, Jeraisy M, Development and Validation of Novel HPLC and Extraction Method for Determination of UC781 in Vaginal Tissue, JPB Sciences, 1; 1 (2012) 27. 8. Rezk NL, Development and validation of LC-ESI-MS method for sensitive, accurate and rapid determination of UC-781 in New Zealand white rabbit plasma, Talanta, 85 (2011) 2074 9. Choi SO, Rezk N, Kim JS, Kashuba AD, Develpoment of an LC-MS method for measuring TNF in Human Vaginal Tissue, J Chromatogr Sci. 48;3 (2010) 219-223. 10. Twigg HL, Schnizlein-Bick CT, Weiden M, Valentine F, Wheat J, Day RB, Rominger H, Zheng L, Collman RG, Coombs RW, Bucy RP, Rezk NL, Kashuba AD, Measurement of antiretroviral drugs in the lungs of HIV-infected patients HIV Ther. Mar 1: 4 ;2 (2010) 247-251. 11. Dumond JB, Vourvahis M, Rezk NL, Paterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuaba AD, A Phenotype-genotype approach to predicting CYP450 and P-glucoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir, Clin Pharmacol Ther. 87; 6 (2010) 735-742. 12. Corbett AH, Hosseinipour MC, Nyrenda J, Kanyama C, Rezk NL, Mkupani P, Sichali D, Tien H, Kashuba AD, Mwansambo C, Weigel R, Kazembe P, Pharmacokinetics of generic and trade

- 13 -

formulations of lamivudine and nevirapine in HIV-infected Malawian children, Antivir Ther. 15; 1

(2010) 83-90.

13. McRae M, Rezk NL, Bridges AS, Corbett AH, Tien HC, Brouwer KL, Kashuba AD, Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity, Pharmacotherapy, 30;1 (2010)17-24. 14. Talameh JA, Pharm D, Rezk NL, PhD, Kashuba DM, Pharm D, Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection J. Chromatoger B Analyt Technol Biomed Life Sci (2010) 1:878(1):92-6. 15. Paul Leger, MD, MPH, Rebecca Dillingham, MD, MPH, Carole Anne Beauharnais, MD, Angela D. M. Kashuba, Pharm D, Naser L. Rezk, PhD, Daniel W.Fitzgerald, MD, Jean William Pape, MD, and David W. Haas, MD, Cyp2B6 Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port-au-Prince, Haiti, JID 200 (2009) 955. 16. Rezk NL, White N, Jennings S, Kashuba A, A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma, Talanta,79 (2009)1372. 17. Shouhdary SK, Rezk NL, Ince LW. Cheema M, Zhang L, Su L, Swabstrom R, Kashuba DMA, Margolis D, Suppression of HIV-1 viremia with reverse transcriptase inhibitors, CD4* T Cell recovery, and viral rebound upon therapy interruption in a new model for HIV treatment in the humanized Rag2 -/- Уc -/- mice, J Virol. 83;16 (2009) 8254 18. Kwara A, Lartey M, Lartey M, Boamah I, Rezk NL, Court M., Oliver-Commey J, Kenu E, Kashuba A, Court M, Interindividual Variability in Pharmacokineticks of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV Co-infected Ghanaian patients, JCP.(2009) 19. Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvagis M., Horton AL, Fiscus SA, Patterson KB, Genital Tract, Cord Blood, and Amniotic Fluid Exposures of

- 14 -

Seven Antiretroviral Drugs during and after Pregnancy in HIV-1 infected Women, Antimicrob Agents Chemother, 2009

20. Choi SO, Rezk NL, Kim J. Kashuba ADM, Development of a LC-MS method for measuring TNF in human vaginal tissue. JCS 2009

21. Kwara A, Lartey M., Kwamena Sagoe, Rezk NL, Court M., CYP2B6 (c.516G T) and CYP2A6

(*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. BJCP.2009

22. Rezk NL, White N, Kashuba A, An accurate and precise high performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. Anal Chim Acta, 2008 Nov3:628(2):204-13 23. Rezk NL, White N, Bridges AS, Abdel-Megeed MF, Mohamed TM, Moselhy SS, Kashuba AD. Studies on Antiretroviral Drug Concentrations in Breast Milk: Validation of a Liquid Chromatography-Tandem Mass Spectrometric Method for the Determination of 7 Anti-Human Immunodeficiency Virus Medications Ther Drug Monit, 2008 Aug 27. 24. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel, PLoS Med. 2008 Aug 5; 5(8):e157; discussion e157.

25. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, P, Rezk NL, Kashuba A, Anton P, McGowan, Shattock R, Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel, PLoS Medicine 2008 August 5;8: 165-167.

26. DiCenzo R, Peteson D, Cruttenden K, Mariuz P, Rezk NL, Hochreiter J, Gelbard H, Schifitto G. Effect of minocycline and valporic acid coadministration on atazanavir plasma concentrations in HIV-ifectd adults receiving atazanavir/Ritonavir, Antimicrob. Agents Chemother. 2008 Jun 23. 27. Tappouni A, Rublein JC, Donovan BJ, Hollowell SB, Tien HC, Min SS, Theodore D, Rezk NL, Smith PC, Tallman MN, Raasch RH, Kashuba AD. Effect of omeprazole on the plasma

- 15 -

concentrations of indinavir when administered alone and in combination with ritonavir, Am J Health Syst Pharm. 2008 Mar 1:65 (5):422-128.

28. Kwara A, DeLong A, Rezk NL, Hogan J, Burtwell H, Champan S, Moreira C, Kurpewski J, Ingersoll J, Caliendo A, Kashuba A, Susan Cu-Uvin, Antiretroviral Drug Concentrations and Virologic Rebound in the Genital Tract of HIV-Infected Women, Clin Infect Dis. 2008 Mar 1;46(5):719-25. 29. Vourvahis M, Tappouni H, Patterson K, Chen Y, Rezk NL, Fiscus S, Kearney B, Rooney J, Hui J, Cohen M, Kashuba A, Tenofovir Pharmacokinetics in the Genital Tract: Implication for Transmission Prevention, JAIDS,2008

30. Dumond J, Yeh R., Patterson K, Corbett A, Jung B, Rezk NL, Bridges A, Stewart P, Cohen M, Kashuba ADM, Antiretroviral Drug Exposure in the Female Genital Tract: Implications for Oral Pre- and Post-Exposure Prophylaxis, AIDS, 2007 Sep 12:21(14):1899-907. 31. Rezk NL, Abdel-Megeed M, Kashuba ADM. Development of a highly efficient extraction technique and specific multiplex assy for measuring drug concentrations in breast milk. Ther Drug Monit, 2007 Aug 29(24):429-36.

32. Jung BH, Rezk NL, Bridges AS, Kashuba ADM, Simultaneous determination of 16 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry, Biomed Chromatogr, 21;20 (2007) 1095. 33. Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, Van der Horst C, Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian subjects. AIDS, 21; 1 (2007) 59-64. 34. Choi SO, Rezk NL, Kashuba ADM, High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications

J Pharm Biomed Anal. 43-200*-****-****.

35. Rezk NL, Brown, K, Kashuba, ADM, A simple and sensitive bioanalytical assay for simultaneous quantitative determination of omeprazole and its three metabolites in human blood plasma using RP- HPLC after an optimized liquid-liquid extraction procedure. J Chromatogr B 2006; 5,844 (2); 314- 321.

36. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Klein C, Rublein J, Kashuba ADM. Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes

- 16 -

(CYP) 2C9, CYP2C19, and CYP1A2, but Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. JAIDS 2006; 42:52-60. 37. Rezk N, Crutchley R, Yeh RF, Kashuba ADM. Full Validation of an Analytical Method For The HIV Protease Inhibitor Atazanavir In Combination With 8 Other Antiretroviral Agents and Its Applicability to Therapeutic Drug Monitoring. Ther Drug Monit, 2006 Aug; 28(4):517-25. 38. Rezk NL, Crutchley RD, Kashuba ADM. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction, Journal of Chromatography B 2005; 822:201-208.

39. Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, Kashuba ADM. Protease inhibitor and Nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV- 1 infected women. J AIDS 2004; 37(5):1577-1580.

40. Rezk NL, Tidwell RR, Kashuba ADM. High-Performance Liquid Chromatography Assay For The Quantification Of HIV Protease Inhibitors And Non-Nucleoside Reverse Transcriptase Inhibitors In Human Plasma J Chromatogr B Analyt Technol Biomed Life Sci 2004;805(2):241-247. 41. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba ADM, The Pharmacokinetics, Safety, and Initial Virologic Response of A Triple-Protease Inhibitor Salvage Regimen Containing Amprenavir, Saquinavir, and Ritonavir, J Acquir Immune Defic Syndr 2004;36:921–928. 42. Rezk NL, Tidwell RR, Kashuba ADM. Simultaneous Determination of Six HIV Nucleoside Analogue Reverse Transcriptase Inhibitors and Nevirapine by Liquid Chromatography with Ultraviolet Detection after Solid-Phase Extraction. J Chromatogr B 2003; 791:137–147. 43. Rezk NL, Tidwell RR, Kashuba ADM. Simple and rapid quantification of the nonnucleoside reverse transciptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma

Contact this candidate